190 related articles for article (PubMed ID: 26075443)
1. Schwannomas exhibit distinct size-dependent gene-expression patterns.
Mehrian-Shai R; Freedman S; Shams S; Doherty J; Slattery W; Hsu NY; Reichardt JK; Andalibi A; Toren A
Future Oncol; 2015; 11(12):1751-8. PubMed ID: 26075443
[TBL] [Abstract][Full Text] [Related]
2. cDNA microarray analysis of vestibular schwannomas.
Welling DB; Lasak JM; Akhmametyeva E; Ghaheri B; Chang LS
Otol Neurotol; 2002 Sep; 23(5):736-48. PubMed ID: 12218628
[TBL] [Abstract][Full Text] [Related]
3. Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas.
Dewan R; Pemov A; Kim HJ; Morgan KL; Vasquez RA; Chittiboina P; Wang X; Chandrasekharappa SC; Ray-Chaudhury A; Butman JA; Stewart DR; Asthagiri AR
Neuro Oncol; 2015 Apr; 17(4):566-73. PubMed ID: 25452392
[TBL] [Abstract][Full Text] [Related]
4. Integrated Analysis of Transcriptome and Differential Methylation of Neurofibromatosis Type 2 Vestibular Schwannomas.
Shi J; Lu D; Gu R; Xie J; Yu L; Sun X; Zhang Y
World Neurosurg; 2022 Jan; 157():e66-e76. PubMed ID: 34587518
[TBL] [Abstract][Full Text] [Related]
5. Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2.
Baser ME; Makariou EV; Parry DM
J Neurosurg; 2002 Feb; 96(2):217-22. PubMed ID: 11838793
[TBL] [Abstract][Full Text] [Related]
6. Molecular biology of vestibular schwannomas.
Chang LS; Welling DB
Methods Mol Biol; 2009; 493():163-77. PubMed ID: 18839347
[TBL] [Abstract][Full Text] [Related]
7. Unilateral vestibular schwannoma with other neurofibromatosis type 2-related tumors: clinical and molecular study of a unique phenotype.
Aghi M; Kluwe L; Webster MT; Jacoby LB; Barker FG; Ojemann RG; Mautner VF; MacCollin M
J Neurosurg; 2006 Feb; 104(2):201-7. PubMed ID: 16509493
[TBL] [Abstract][Full Text] [Related]
8. Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study.
Mautner VF; Baser ME; Thakkar SD; Feigen UM; Friedman JM; Kluwe L
J Neurosurg; 2002 Feb; 96(2):223-8. PubMed ID: 11838794
[TBL] [Abstract][Full Text] [Related]
9. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
[TBL] [Abstract][Full Text] [Related]
10. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
Fisher LM; Doherty JK; Lev MH; Slattery WH
Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
[TBL] [Abstract][Full Text] [Related]
11. The molecular biology and novel treatments of vestibular schwannomas.
Fong B; Barkhoudarian G; Pezeshkian P; Parsa AT; Gopen Q; Yang I
J Neurosurg; 2011 Nov; 115(5):906-14. PubMed ID: 21800959
[TBL] [Abstract][Full Text] [Related]
12. Neurofibromatosis type 2 in an infant with multiple plexiform schwannomas as first symptom.
Miyakawa T; Kamada N; Kobayashi T; Hirano K; Fujii K; Sasahara Y; Nagai Y; Shinkai H
J Dermatol; 2007 Jan; 34(1):60-4. PubMed ID: 17204104
[TBL] [Abstract][Full Text] [Related]
13. Somatic neurofibromatosis type 2 gene mutations and growth characteristics in vestibular schwannoma.
Irving RM; Harada T; Moffat DA; Hardy DG; Whittaker JL; Xuereb JH; Maher ER
Am J Otol; 1997 Nov; 18(6):754-60. PubMed ID: 9391673
[TBL] [Abstract][Full Text] [Related]
14. NF2 genetic alterations in sporadic vestibular schwannomas: clinical implications.
Lassaletta L; Torres-Martín M; Peña-Granero C; Roda JM; Santa-Cruz-Ruiz S; Castresana JS; Gavilan J; Rey JA
Otol Neurotol; 2013 Sep; 34(7):1355-61. PubMed ID: 23921927
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
Sirén V; Antinheimo JP; Jääskeläinen J; Böhling T; Carpén O; Vaheri A
Acta Neurochir (Wien); 2004 Feb; 146(2):111-8. PubMed ID: 14963743
[TBL] [Abstract][Full Text] [Related]
16. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
[TBL] [Abstract][Full Text] [Related]
17. Gene discovery using a human vestibular schwannoma cDNA library constructed from a patient with neurofibromatosis type 2 (NF2).
Halum SL; Erbe CB; Friedland DR; Wackym PA
Otolaryngol Head Neck Surg; 2003 Mar; 128(3):364-71. PubMed ID: 12646839
[TBL] [Abstract][Full Text] [Related]
18. Genetic and epigenetic alterations of the NF2 gene in sporadic vestibular schwannomas.
Lee JD; Kwon TJ; Kim UK; Lee WS
PLoS One; 2012; 7(1):e30418. PubMed ID: 22295085
[TBL] [Abstract][Full Text] [Related]
19. Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas.
Cumpston EC; Rhodes SD; Yates CW
Curr Oncol Rep; 2023 May; 25(5):531-537. PubMed ID: 36933171
[TBL] [Abstract][Full Text] [Related]
20. Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma.
Irving RM; Moffat DA; Hardy DG; Barton DE; Xuereb JH; Maher ER
Hum Mol Genet; 1994 Feb; 3(2):347-50. PubMed ID: 8004107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
